Immunotherapy is a rapidly evolving field that mandates frequent revision of the book as new insights to fight cancer emerge. The third edition of Immunotherapy is an updated overview of immuno-oncology in different cancer types and toxicities associated with immunotherapy. It explores the breath of immunotherapeutic strategies available to treat a wide range of cancers, from melanoma and non-small cell lung cancer to gastrointestinal, genitourinary, gynecologic and nervous system malignancies. With increasing use of checkpoint inhibitors as standard of care and in clinical trials, the challenges associated with their use undoubtedly increase. As objective response is limited to a subset of patients and is often associated with distinct immune related side effects that are potentially life threatening, it is essential to identify patients who are likely to respond to immunotherapy and those who are at a risk for developing treatment-related side effects. In the absence of a validated predictive biomarker, innovative technologies and assays are being used to identify critical biomarkers that drive the immune response. Hence, a chapter to provide a basic understanding of the diagnostic procedures has been included besides the chapter on the cellular components of the human immune system. This new edition will also inform readers on use of novel microbiome and imaging approaches. Finally, the book includes a chapter on patient-reported outcomes in patients treated with immunotherapies as the authors recognize the importance of including missing patient voice in clinical trials and longitudinal assessment of symptom reports. In short, the third edition of this book provides a comprehensive overview of the latest developments in the field of immune-oncology that will help health care professionals make informed treatment decisions.
The book's chapters are written by a diverse cast of experts conducting cutting-edge research, providing the reader with the most up-to-date science.
Dr. Aung Naing is an Associate Professor in the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center and is also a Principal Investigator on immunotherapy-based clinical trials. Focusing on clinical translation of basic immunobiology, Dr. Naing's research interests are (1) identifying immunologic biomarkers of response to immunotherapy, (2) predicting primary and secondary resistance to immunotherapy, (3) developing immunotherapeutic strategies to overcome resistance, and (4) identifying predictive markers for immune-related adverse events (irAE) associated with immunotherapies.
Dr. Joud Hajjar is an Assistant Professor of Allergy and Immunology and serves as the service chief of adult allergy and immunology at Texas Children's Hospital. She is a member of the Basic and Clinical Immunology Interest group at the American Academy of Allergy Asthma and Immunology, and the Early Career Immunologist Committee at the Clinical Immunology Society. Dr. Hajjar's research interests are in primary immunodeficiency disorders, and cancer immunotherapy.
1. Overview of Basic Immunology and Clinical Application
2. Advances in Diagnostic Procedures and their Applications in the era of Cancer Immunotherapy3. Immunotherapy for Melanoma4. Immunotherapy in Lung Cancer: From a minor God to the Olympus5. Immunotherapy in Gastrointestinal Malignancies6. Current Landscape of Immunotherapy in Genitourinary Malignancies7. Immuno-oncology for Gynecologic Malignancies8. Immunotherapy for Neuro-Oncology 9. Immunotherapy and Radiation10. CAR T-cells11. Skin Reactions to Immune Checkpoint Inhibitors12. Gastrointestinal Tract Adverse Events13. Immune-Related Adverse Events: Pneumonitis14. Hepatobiliary Adverse Events15. Immune Checkpoint Inhibitors (ICIs) Related Cardiotoxicity16. Renal Toxicity17. Immune-Related Oral, Otologic and Ocular Adverse Events 18. Cancer Imaging in Immunotherapy19. The Microbiome in Immuno-Oncology 20. New developments in the use of Patient-reported outcomes in Cancer Patients undergoing Immunotherapies